Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02262741
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : October 23, 2017
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head and Neck Biological: MEDI4736 Biological: tremelimumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Actual Study Start Date : October 15, 2014
Actual Primary Completion Date : September 21, 2017
Actual Study Completion Date : September 21, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: MEDI4736 + tremelimumab Biological: MEDI4736
MEDI4736 will be administered by IV infusion in combination with tremelimumab.

Biological: tremelimumab
Tremelimumab will be administered by IV infusion in combination with MEDI4736.




Primary Outcome Measures :
  1. Number of subjects reporting adverse events [ Time Frame: Screening through 3 months after the last dose of study medication ]
  2. Number of subjects reporting serious adverse events [ Time Frame: Screening through 3 months after the last dose of study medication ]
  3. Number of subjects experiencing dose-limiting toxicities [ Time Frame: First dose of study medications through 4 weeks after the first dose of study medication ]
  4. Change from Baseline in laboratory evaluations [ Time Frame: Screening through 3 months after the last dose of study medication ]
  5. Change from Baseline in electrocardiograms [ Time Frame: Screening through 3 months through last dose of study medication ]
  6. Change from Baseline in vital signs [ Time Frame: Screening through 3 months after the last dose of study medication ]

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Screening through 5 years after the last subject receives the first dose of study medication ]
  2. Individual MEDI4736 concentrations [ Time Frame: First dose of MEDI4736 through 3 months after the last dose of study medication ]
  3. Number of subjects that develop changes in detectable antidrug antibodies to MEDI4736 [ Time Frame: First dose of MEDI4736 through 6 months after the last dose of study medication ]
  4. Disease Control Rate [ Time Frame: Screening through 5 years after the last subject receives the first dose of study medication ]
  5. Duration of Response [ Time Frame: Screening through 5 years after the last subject receives the first dose of study medication ]
  6. Progression Free Survival [ Time Frame: Screening through 5 years after the last subject receives the first dose of study medication ]
  7. Overall Survival [ Time Frame: Screening through 5 years after the last subject receives the first dose of study medication ]
  8. Individual tremelimumab concentrations [ Time Frame: First dose of tremelimumab through 3 months after the last dose of study medication ]
  9. MEDI4736 area under the concentration-curve [ Time Frame: First dose of MEDI4736 through 3 months after the last dose of study medication ]
  10. Tremelimumab area under the concentration-curve [ Time Frame: First dose of tremelimumb through 3 months after the last dose of study medication ]
  11. Number of subjects that develop changes in detectable antidrug antibodies to tremelimumab [ Time Frame: First dose of tremelimumab through 6 months after the last dose of study medication ]

Other Outcome Measures:
  1. Changes in Biomarkers [ Time Frame: Screening through 3 months after the last patient receives the first dose of study medication ]
    Evaluate biomarkers that may correlate with clinical activity of MEDI4736 monotherapy and in combination with tremelimumab

  2. Change from Baseline in Patient-Reported Outcomes [ Time Frame: Screening through 5 years after the last patient receives the first dose of study medication ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects
  2. 18 years and older
  3. Histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) that is incurable by local therapy.
  4. Subjects who are treatment-naive or pretreated (prior anti-PD-1 or anti-PD-L1 required) in the recurrent/metastatic setting.
  5. Subject eligibility will be based on PD-L1 expression as determined by a specified IHC assay.

Exclusion Criteria:

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, receipt of last dose of an approved anticancer therapy within 21 days
  2. Concurrent or prior use of immunosuppressive medication within 14 days
  3. Active or prior documented autoimmune or inflammatory disease within 3 years with some exceptions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02262741


Locations
Layout table for location information
United States, Arizona
Research Site
Scottsdale, Arizona, United States, 85258
United States, California
Research Site
La Jolla, California, United States, 92093
Research Site
Los Angeles, California, United States, 90025
Research Site
Los Angeles, California, United States, 90095
Research Site
San Francisco, California, United States, 94143
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06520
United States, Florida
Research Site
Orlando, Florida, United States, 32806
United States, Illinois
Research Site
Chicago, Illinois, United States, 60611
United States, Kansas
Research Site
Fairway, Kansas, United States, 66205
United States, Louisiana
Research Site
New Orleans, Louisiana, United States, 70112
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21287
United States, Michigan
Research Site
Detroit, Michigan, United States, 48201
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States, 55455
United States, New York
Research Site
New York, New York, United States, 10016
Research Site
New York, New York, United States, 10065
United States, Oregon
Research Site
Portland, Oregon, United States, 97213
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19111
United States, South Carolina
Research Site
Greenville, South Carolina, United States, 29605
United States, Texas
Research Site
San Antonio, Texas, United States, 78229
United States, Virginia
Research Site
Fairfax, Virginia, United States, 22031
Canada, Ontario
Research Site
London, Ontario, Canada, N6A 4L6
Research Site
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
MedImmune LLC
Investigators
Layout table for investigator information
Study Director: MedImmune LLC MedImmune LLC
Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT02262741    
Other Study ID Numbers: D4190C00011
First Posted: October 13, 2014    Key Record Dates
Last Update Posted: October 23, 2017
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Durvalumab
Tremelimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents